Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 23, Issue 10, Pages 1261-1273
Publisher
Elsevier BV
Online
2022-09-13
DOI
10.1016/s1470-2045(22)00541-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
- (2022) V. Subbiah et al. ANNALS OF ONCOLOGY
- Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors
- (2022) George D. Demetri et al. CLINICAL CANCER RESEARCH
- The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
- (2022) Ezra Y. Rosen et al. Nature Communications
- Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
- (2021) Vivek Subbiah et al. CLINICAL CANCER RESEARCH
- Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing
- (2021) Jing Wang et al. Journal of Translational Medicine
- Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
- (2021) Patrick Y Wen et al. LANCET ONCOLOGY
- Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
- (2021) Claire F. Friedman et al. Cancer Discovery
- Recurrent RET Gene Fusions in Pediatric Spindle Mesenchymal Neoplasms
- (2020) Jessica L. Davis et al. HISTOPATHOLOGY
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
- (2020) Massimo Santoro et al. Genes
- Selpercatinib: First Approval
- (2020) Anthony Markham DRUGS
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
- (2020) Lori J. Wirth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
- (2020) Ana Oaknin et al. JAMA Oncology
- Colorectal carcinomas containing hypermethylated MLH1 promoter and wild type BRAF/KRAS are enriched for targetable kinase fusions
- (2019) Emiliano Cocco et al. CANCER RESEARCH
- REToma: a cancer subtype with a shared driver oncogene
- (2019) Takashi Kohno et al. CARCINOGENESIS
- Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
- (2019) Benjamin H. Durham et al. NATURE MEDICINE
- RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
- (2018) F Pietrantonio et al. ANNALS OF ONCOLOGY
- Selective RET kinase inhibition for patients with RET-altered cancers
- (2018) V Subbiah et al. ANNALS OF ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
- (2018) Michael M. Boyiadzis et al. Journal for ImmunoTherapy of Cancer
- Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck
- (2017) Min Hee Hong et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
- (2017) Alison M. Schram et al. Nature Reviews Clinical Oncology
- Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
- (2017) Alexander Drilon et al. Nature Reviews Clinical Oncology
- RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
- (2016) Shumei Kato et al. CLINICAL CANCER RESEARCH
- RET/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease
- (2016) Xuan Su et al. PLoS One
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now